Concentrix Corporation (NASDAQ: CNXC) announced today that members of its senior management team will participate in several upcoming investor conferences.

Cwm LLC trimmed its stake in Concentrix Corporation (NASDAQ: CNXC) by 56.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 37,468 shares of the company's stock after selling 49,042 shares during the period. Cwm LLC owned 0.06% of Concentrix worth $1,558,000 at the

Investors need to pay close attention to CNXC stock based on the movements in the options market lately.

Taiwan Semiconductor is a giant chip maker with great growth prospects. Concentrix is facing some challenges, but offers a fat dividend yield.

BrightView (NYSE: BV - Get Free Report) and Concentrix (NASDAQ: CNXC - Get Free Report) are both small-cap business services companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings. Analyst Ratings This is a breakdown of recent

Concentrix (NASDAQ: CNXC - Get Free Report) and BrightView (NYSE: BV - Get Free Report) are both small-cap business services companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings. Insider and Institutional Ownership 90.3% of Concentrix shares

AI skepticism doesn't mean no opportunity. These two tickers have value where the market isn't looking.

Concentrix reported quarterly adjusted earnings of $2.61 per share, which missed the Street estimate of $2.65. Quarterly revenue was $2.500 billion, up by 5.4% year-over-year (Y/Y), above the analyst consensus estimate of $2.492 billion.

Concentrix Corporation is rated Hold as it undergoes a complex, costly transition to AI-driven customer experience solutions, with investor confidence shaken by execution risks. Despite a 5.4% YoY revenue increase and a forward P/E of ~2x, CNXC faces margin pressure, negative Q1 free cash flow, and high leverage, justifying its deep discount. Q2 guidance remains below consensus, and the investment thesis now hinges on a second-half 2026 recovery in margins and cash flows to validate the turnaround.

Concentrix trades at extremely low valuation multiples, but its deep value is tempered by significant debt concerns. Concentrix continues to post organic revenue growth, though guidance for FY'26 was modestly below consensus on both the top and bottom lines. GAAP profitability and cash flow are materially lower than non-GAAP figures. Debt service further constrains shareholder returns.